当飞利肝宁胶囊联合壳脂胶囊治疗非酒精性脂肪性肝病疗效观察  

Observation on Curative Effect of "Dangfei Liganning" Capsule Combined "Kezhi" Capsule in Treatment of Non-alcoholic Fatty Liver Disease

作　　者：陈炘[1] 周小茜[1] 戴福宏[1] 王超秀[1] 

机构地区：[1]内江市第一人民医院感染科,四川内江646000

出　　处：《临床医药文献电子杂志》2017年第34期6545-6546,6548,共3页Electronic Journal of Clinical Medical Literature

摘　　要：目的观察当飞利肝宁胶囊、壳脂胶囊治疗非酒精性脂肪性肝病的临床疗效。方法选择符合标准的非酒精性脂肪性肝病门诊患者51例,患者自愿选药,按用药情况分为当飞利肝宁胶囊组17例、壳脂胶囊治疗组17例、当飞利肝宁胶囊联合壳脂胶囊治疗组(联合治疗组)17例。治疗方法:当飞利肝宁胶囊1.0 g tid、壳脂胶囊1.25 g tid,疗程共24周,于第12周、24周测定丙氨酸氨基转移酶(ALT)、甘油三脂(TG)、脂肪肝受控衰减参数(CAP)。结果三组治疗方案在降低ALT、TG、CAP方面均有显著疗效。当飞利肝宁胶囊组显示出了较好的降低ALT的作用,差异有统计学意义(P<0.05);壳脂胶囊组则在降低TG及CAP方面显示出了优势,差异有统计学意义(P<0.05);联合治疗组疗效优于单药组,差异有统计学意义(P<0.05)。结论当飞利肝宁胶囊联合壳脂胶囊治疗NAFLD效果好,优于单药治疗。Objective To observe the clinical efficacy of ＂Dangfei Liganning＂ capsule and ＂Kezhi＂ capsule in the treatment of non-alcoholic fatty hver disease（NAFLD）.Methods 51 NAFLD cases of outpatients were divided to three groups by voluntary drug selection,They are ＂Dangfei Liganning＂ capsule group,＂Kezhi＂ capsule group and ＂Dangfei Liganning＂ capsule combined with ＂Kezhi＂ capsule group （combined treatment group） ,and each group contains 17 cases.Treatment methods： ＂Dangfei Liganning＂ capsule （1.0g,tid,po） and ＂Kezhi＂ capsule （1.25 g,tid,po）,the treatment lasted for 24 weeks.ALT, TG and controlled attenuation parameters （CAP） were tested at 12th and 24th weeks.Results The three groups had significant effect on reducing ALT, TG and CAP.＂Dangfei Liganning＂ capsule group show better reduce the role of ALT （P〈0.05）;＂Kezhi＂ capsule group in reducing TG and CAP show advantages （P〈0.05）;combined treatment group is better than the single drug group （P〈0.05）. Conclusion ＂Dangfei Liganning＂ capsule combined with ＂Kezhi＂ capsule capsule is better than that of single drug treatment for the treatment of patients with NAFLD.

关 键 词：非酒精性脂肪性肝病 壳脂胶囊 当飞利肝宁胶囊 

分 类 号：R575.5[医药卫生—消化系统]